Five Prime Therapeutics Company Profile (NASDAQ:FPRX)

About Five Prime Therapeutics

Five Prime Therapeutics logoFive Prime Therapeutics, Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations. The Company seeks to engage third-party collaborators to assist it in developing companion diagnostics for its clinical programs. The Company's product candidates include FPA008, FPA144 and FP-1039/GSK3052230. The FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1), receptor (CSF1R). The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). FP-1039 is a protein therapeutic designed to trap and neutralize cancer-promoting fibroblast growth factors (FGFs).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FPRX
  • CUSIP:
Key Metrics:
  • Previous Close: $48.51
  • 50 Day Moving Average: $46.96
  • 200 Day Moving Average: $41.68
  • Trailing P/E Ratio: 5.46
  • Foreward P/E Ratio: -13.90
  • P/E Growth: 0.68
  • Market Cap: $1.31B
  • Outstanding Shares: 26,923,000
  • Beta: 4.47
Additional Links:
Companies Related to Five Prime Therapeutics:

Analyst Ratings

Consensus Ratings for Five Prime Therapeutics (NASDAQ:FPRX) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $53.60 (10.49% upside)

Analysts' Ratings History for Five Prime Therapeutics (NASDAQ:FPRX)
Show:
DateFirmActionRatingPrice TargetDetails
8/8/2016Leerink SwannReiterated RatingOutperform$45.00 -> $58.00View Rating Details
8/5/2016Jefferies GroupSet Price TargetBuy$41.00 -> $60.00View Rating Details
7/12/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details
5/19/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$48.00View Rating Details
4/12/2016BMO Capital MarketsInitiated CoverageMarket Perform$50.00View Rating Details
12/4/2015Wells Fargo & Co.Reiterated RatingOutperformView Rating Details
7/31/2015Citigroup Inc.Initiated CoverageNeutral -> Buy$33.00View Rating Details
5/13/2015GuggenheimInitiated CoverageBuy$31.00View Rating Details
(Data available from 8/24/2014 forward)

Earnings

Earnings History for Five Prime Therapeutics (NASDAQ:FPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2016        
8/4/2016Q2($0.56)($0.49)$6.38 million$9.23 millionViewN/AView Earnings Details
5/5/2016Q1($0.71)($0.49)$5.26 million$6.50 millionViewN/AView Earnings Details
3/10/2016Q4$9.67$10.63$354.16 million$363.34 millionViewListenView Earnings Details
11/4/2015Q315($0.99)($0.93)$4.90 million$5.90 millionViewN/AView Earnings Details
8/6/2015Q215($0.44)($0.45)$6.92 million$6.30 millionViewN/AView Earnings Details
5/13/2015Q1($0.53)($0.44)$4.77 million$4.30 millionViewListenView Earnings Details
3/17/2015Q414($0.10)($0.55)$4.65 millionViewN/AView Earnings Details
11/10/2014($0.40)($0.33)ViewN/AView Earnings Details
8/5/2014Q2 14($0.27)($0.46)ViewN/AView Earnings Details
3/25/2014Q4($0.40)($0.43)ViewListenView Earnings Details
11/12/2013($0.57)($2.74)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Five Prime Therapeutics (NASDAQ:FPRX)
Current Year EPS Consensus Estimate: $-2.07 EPS
Next Year EPS Consensus Estimate: $-3.49 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.87)($0.46)($0.62)
Q2 20162($0.76)($0.57)($0.67)
Q3 20163($0.80)($0.53)($0.65)
Q4 20163($1.38)($0.59)($0.88)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Five Prime Therapeutics (NASDAQ:FPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Five Prime Therapeutics (NASDAQ:FPRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/1/2016William R RingoDirectorSell500$50.77$25,385.00View SEC Filing  
7/27/2016Peder JensenDirectorSell12,195$49.50$603,652.50View SEC Filing  
4/22/2016Franklin M BergerDirectorBuy5,000$49.47$247,350.00View SEC Filing  
4/22/2016Marc BelskyCFOSell34,102$50.00$1,705,100.00View SEC Filing  
4/21/2016Lewis T WilliamsCEOSell48,671$48.05$2,338,641.55View SEC Filing  
4/19/2016Franklin M BergerDirectorBuy6,090$47.06$286,595.40View SEC Filing  
4/15/2016Lewis T WilliamsCEOSell1,405$48.00$67,440.00View SEC Filing  
4/14/2016Lewis T WilliamsCEOSell2,725$48.00$130,800.00View SEC Filing  
4/6/2016Lewis T WilliamsCEOSell52,801$43.09$2,275,195.09View SEC Filing  
4/6/2016Marc BelskyCFOSell20,814$45.04$937,462.56View SEC Filing  
3/30/2016Francis Willard SarenaEVPSell10,000$40.01$400,100.00View SEC Filing  
3/30/2016Lewis T WilliamsCEOSell23,259$40.02$930,825.18View SEC Filing  
3/30/2016Marc BelskyCFOSell13,876$40.01$555,178.76View SEC Filing  
3/2/2016Lewis T WilliamsCEOSell23,259$36.01$837,556.59View SEC Filing  
2/4/2016Lewis T. WilliamsCEOSell71,229$33.35$2,375,487.15View SEC Filing  
1/27/2016Francis Willard SarenaEVPSell30,000$35.22$1,056,600.00View SEC Filing  
10/15/2015Adage Capital Partners Gp LlcMajor ShareholderSell125,000$27.75$3,468,750.00View SEC Filing  
10/15/2015Lewis T. WilliamsCEOSell72,352$27.24$1,970,868.48View SEC Filing  
9/21/2015Lewis T WilliamsCEOSell2,648$22.06$58,414.88View SEC Filing  
6/22/2015Lewis T WilliamsCEOSell75,000$24.67$1,850,250.00View SEC Filing  
1/28/2015Franklin M BergerDirectorBuy25,000$27.03$675,750.00View SEC Filing  
1/15/2015Franklin M BergerDirectorBuy10,049$26.17$262,982.33View SEC Filing  
11/28/2014Franklin M BergerDirectorBuy1,951$21.04$41,049.04View SEC Filing  
11/4/2014Lewis T WilliamsCEOSell32,603$13.08$426,447.24View SEC Filing  
10/30/2014Lewis T WilliamsCEOSell17,397$13.13$228,422.61View SEC Filing  
9/23/2013Brian G AtwoodDirectorBuy76,923$13.00$999,999.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Five Prime Therapeutics (NASDAQ:FPRX)
DateHeadline
capitalcube.com logoETF’s with exposure to Five Prime Therapeutics, Inc. : August 23, 2016 (NASDAQ:FPRX)
www.capitalcube.com - August 23 at 5:12 PM
investornewswire.com logoWill Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Hit $60 Price Target? - Investor Newswire (NASDAQ:FPRX)
www.investornewswire.com - August 15 at 5:14 PM
fidaily.com logoFive Prime Therapeutics, Inc. (FPRX) Ownership Increased by Fmr ... - Finance Daily (NASDAQ:FPRX)
www.fidaily.com - August 12 at 8:03 AM
capitalcube.com logoETF’s with exposure to Five Prime Therapeutics, Inc. : August 11, 2016 (NASDAQ:FPRX)
www.capitalcube.com - August 11 at 5:17 PM
finance.yahoo.com logoFIVE PRIME THERAPEUTICS INC Financials (NASDAQ:FPRX)
finance.yahoo.com - August 11 at 5:17 PM
seekingalpha.com logoFive Prime Therapeutics Could Be The Ace Up The Sleeve Of Bristol-Myers Squibb (NASDAQ:FPRX)
seekingalpha.com - August 9 at 9:26 PM
forbes.com logoMonday's ETF Movers: XOP, XBI (NASDAQ:FPRX)
www.forbes.com - August 9 at 3:49 PM
capitalcube.com logoFive Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016 (NASDAQ:FPRX)
www.capitalcube.com - August 9 at 3:49 PM
streetupdates.com logoAnalysts Spotlight: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) , Zimmer Biomet Holdings, Inc. (NYSE:ZBH) - Street Updates (NASDAQ:FPRX)
www.streetupdates.com - August 9 at 8:01 AM
feeds.benzinga.com logoMonday's Market Wrap: Stocks Begin Week With Minor Losses (NASDAQ:FPRX)
feeds.benzinga.com - August 8 at 7:03 PM
News IconWorth Watching Stocks to Track: Five Prime Therapeutics Inc (NASDAQ:FPRX), US Foods Holding Corp (NYSE:USFD) - NYSE Journal (press release) (NASDAQ:FPRX)
stockznews.com - August 6 at 5:23 PM
News IconFive Prime Therapeutics Inc. 2Q earnings released (NASDAQ: FPRX) - BNB Daily (blog) (NASDAQ:FPRX)
www.baseball-news-blog.com - August 5 at 5:10 PM
biz.yahoo.com logoFIVE PRIME THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:FPRX)
biz.yahoo.com - August 5 at 5:09 PM
finance.yahoo.com logoEdited Transcript of FPRX earnings conference call or presentation 4-Aug-16 8:30pm GMT (NASDAQ:FPRX)
finance.yahoo.com - August 5 at 5:09 PM
equities.com logoFive Prime Therapeutics Inc. (FPRX) is Trading Lower on Unusual Volume for August 02 - Equities.com (NASDAQ:FPRX)
www.equities.com - August 5 at 5:28 AM
equities.com logoFive Prime Therapeutics Inc. (FPRX) is Trading Higher on Unusual ... - Equities.com (NASDAQ:FPRX)
www.equities.com - August 5 at 5:28 AM
finance.yahoo.com logoFive Prime Therapeutics posts 2Q loss - Yahoo Finance (NASDAQ:FPRX)
finance.yahoo.com - August 4 at 10:50 PM
sg.finance.yahoo.com logoFive Prime Therapeutics posts 2Q loss (NASDAQ:FPRX)
sg.finance.yahoo.com - August 4 at 10:50 PM
prnewswire.com logoResearch Report Initiation on These Biotech Stocks -- Tesaro, Cerus, Five Prime Therapeutics, and Intercept Pharma (NASDAQ:FPRX)
www.prnewswire.com - August 4 at 5:24 PM
twst.com logoFive Prime Therapeutics Inc.: Five Prime Announces Second Quarter 2016 Results and Provides Business Update (NASDAQ:FPRX)
www.twst.com - August 4 at 5:24 PM
publicnow.com logoFive Prime Announces Second Quarter 2016 Results and Provides Business Update (NASDAQ:FPRX)
www.publicnow.com - August 4 at 5:24 PM
equities.com logoFive Prime Therapeutics Inc. (FPRX) Hits New 52-week High During August 01 Session - Equities.com (NASDAQ:FPRX)
www.equities.com - August 4 at 5:19 AM
nasdaq.com logoCommit To Purchase Five Prime Therapeutics At $35, Earn 9.7% Annualized Using Options - Nasdaq (NASDAQ:FPRX)
www.nasdaq.com - August 2 at 10:40 PM
fidaily.com logoInsiders Selling, Short Interest Growing Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Finance Daily (NASDAQ:FPRX)
www.fidaily.com - August 2 at 10:40 PM
nasdaq.com logoCommit To Purchase Five Prime Therapeutics At $35, Earn 9.7% Annualized Using Options (NASDAQ:FPRX)
www.nasdaq.com - August 2 at 5:20 PM
streetreport.co logoIs it the Best Time to Buy Five Prime Therapeutics Inc (NASDAQ:FPRX)? - Street Report (NASDAQ:FPRX)
www.streetreport.co - August 2 at 5:20 PM
News IconIt's Earnings Time: What to Do with Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Stock - The Voice Registrar (NASDAQ:FPRX)
voiceregistrar.com - August 1 at 5:00 PM
investornewswire.com logoCan Shares Of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Hit $50? - Investor Newswire (NASDAQ:FPRX)
www.investornewswire.com - July 25 at 10:36 PM
News IconEcor1 Capital LLC Decreased Stake in Five Prime Therapeutics INC (NASDAQ:FPRX) by $8.73 Million as Shares Rose - Press Telegraph (NASDAQ:FPRX)
presstelegraph.com - July 23 at 9:09 AM
News IconHays Advisory adds Five Prime Therapeutics Inc (FPRX) to its portfolio - TheFounders Daily (NASDAQ:FPRX)
www.thefoundersdaily.com - July 23 at 9:09 AM
fiscalstandard.com logoFive Prime Therapeutics, Inc. (NASDAQ:FPRX) Current Analyst Ratings - Fiscal Standard (NASDAQ:FPRX)
www.fiscalstandard.com - July 22 at 5:34 AM
news.cmlviz.com logoFive Prime Therapeutics Inc (NASDAQ:FPRX) Price Volatility Hits An Elevated Level - CML News (NASDAQ:FPRX)
news.cmlviz.com - July 21 at 5:14 PM
capitalcube.com logoETF’s with exposure to Five Prime Therapeutics, Inc. : July 21, 2016 (NASDAQ:FPRX)
www.capitalcube.com - July 21 at 2:03 PM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - TGP (NASDAQ:FPRX)
telanaganapress.com - July 21 at 8:37 AM
News IconFive Prime Therapeutics Inc Just Recorded A Sigfniciant Increase - Press Telegraph (NASDAQ:FPRX)
presstelegraph.com - July 21 at 8:37 AM
News IconIncreased Stock Volatility Watch: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Engelwood Daily (NASDAQ:FPRX)
www.engelwooddaily.com - July 20 at 6:27 PM
News IconTrading Performance and Target Watch for Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Press Telegraph (NASDAQ:FPRX)
presstelegraph.com - July 20 at 5:28 AM
News IconFive Prime Therapeutics, Inc. (NASDAQ:FPRX): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:FPRX)
www.engelwooddaily.com - July 20 at 5:28 AM
investornewswire.com logoIs $50 Price Target Attainable For Five Prime Therapeutics, Inc. (NASDAQ:FPRX)? - Investor Newswire (NASDAQ:FPRX)
www.investornewswire.com - July 20 at 5:28 AM
nasdaq.com logoFPRX Crosses Above Average Analyst Target (NASDAQ:FPRX)
www.nasdaq.com - July 19 at 11:09 AM
finance.yahoo.com logoFive Prime Therapeutics to Announce Second Quarter 2016 Financial Results and Host Conference Call on August 4 (NASDAQ:FPRX)
finance.yahoo.com - July 18 at 4:05 PM
News IconEcor1 Capital LLC Decreased Stake in Five Prime Therapeutics INC (NASDAQ:FPRX) by $8.73 Million as Shares Rose - Consumer Eagle (NASDAQ:FPRX)
www.consumereagle.com - July 16 at 4:55 PM
streetreport.co logoCan Five Prime Therapeutics Inc (NASDAQ:FPRX) Continue to Deliver Results? - Street Report (NASDAQ:FPRX)
www.streetreport.co - July 15 at 4:06 PM
publicnow.com logoGSK Exclusively Licenses Intellectual Property for Respiratory Disease Target Identified Using Five Prime's Proprietary Protein Discovery Platform (NASDAQ:FPRX)
www.publicnow.com - July 14 at 5:38 PM
News IconCrowd Rating and Earnings Recap for Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Telanagana Press (NASDAQ:FPRX)
telanaganapress.com - July 14 at 5:12 PM
streetinsider.com logoFive Prime Therapeutics (FPRX) Says Glaxo (GSK) Exercised Right to Take Exclusive License of Proprietary Protein ... - StreetInsider.com (NASDAQ:FPRX)
www.streetinsider.com - July 14 at 5:12 PM
finance.yahoo.com logoGSK Exclusively Licenses Intellectual Property for Respiratory Disease Target Identified Using Five Prime’s Proprietary Protein Discovery Platform (NASDAQ:FPRX)
finance.yahoo.com - July 14 at 5:00 PM
News IconAnalyst Target and Average Rating Watch: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Press Telegraph (NASDAQ:FPRX)
presstelegraph.com - July 13 at 5:46 AM
News IconFive Prime Therapeutics, Inc. (NASDAQ:FPRX) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:FPRX)
www.engelwooddaily.com - July 12 at 5:16 PM
News IconStock on the Rise for the Quarter: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Engelwood Daily (NASDAQ:FPRX)
www.engelwooddaily.com - July 11 at 5:08 PM

Social

Five Prime Therapeutics (NASDAQ:FPRX) Chart for Wednesday, August, 24, 2016


Last Updated on 8/24/2016 by MarketBeat.com Staff